STTK, US82024L1035

Shattuck Labs stock fell 5.3 percent as Phase 2 expanded

Published on 10/07/2026 at 00:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Shattuck Labs stock traded at USD 6.3760 on Nasdaq on October 5, 2026. Q2 2026 adjusted EPS was a loss of USD 0.12 per share.

STTK, US82024L1035, Illustration mit AI erstellt.

Shattuck Labs stock (ISIN US82024L1035) was last at USD 6.3760 on Nasdaq on October 5, 2026, down 5.3 percent from USD 6.73. The clinical-stage biotechnology company is extending its lead program SL-325 into another Phase 2 indication.

SL-325 enters another Phase 2 trial

According to GlobeNewswire on October 1, 2026, Shattuck plans to evaluate SL-325 in the RECEPTIVE-HS1 Phase 2 trial for moderate to severe hidradenitis suppurativa. The randomized study will compare two dose levels with placebo over a 16-week treatment period, followed by an extension through Week 52.

The company expects to submit an Investigational New Drug application in October 2026, while Week 16 data are expected in the first half of 2028, according to GlobeNewswire. The same antibody is also being evaluated in a Phase 2 Crohn's disease trial, giving the program two inflammatory disease pathways but leaving important clinical milestones well ahead.

Analyst targets stay above the price

Needham raised its Shattuck Labs price target from USD 17.00 to USD 19.00 and kept a Buy rating on October 2, 2026, as reported by Markets Insider. The USD 19.00 target lies 198.0 percent above the USD 6.3760 price, making the valuation dependent on successful development rather than near-term revenue.

MarketBeat reported a Buy consensus from 12 analysts on October 5, 2026, with two Strong Buy ratings, nine Buy ratings and one Sell rating. The average target was USD 13.33, which lies 109.1 percent above the October 5 price, although the spread between ratings highlights the risk around an early-stage pipeline.

Losses underline the development risk

Shattuck reported adjusted EPS of negative USD 0.12 for Q2 2026, matching consensus estimates, according to MarketBeat. The result places the October 2026 trial filing and the first half of 2028 data window at the center of the investment case, because the company remains in clinical development.

Stock stays below its yearly high

On October 5, 2026, 599,094 shares changed hands as the stock traded as low as USD 6.33, while the 52-week range was USD 1.70 to USD 8.33. The USD 6.3760 last price was 23.5 percent below the yearly high, keeping clinical progress more important than short-term chart strength.

Shattuck Labs stock was last at USD 6.3760 on Nasdaq on October 5, 2026. Its latest quoted range was USD 1.70 to USD 8.33.